Related Experiment Video
Updated: Dec 13, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cisplatin and S-1 for urachal carcinoma: A single-institution case series
Tetsuya Urasaki1, Yoichi Naito1,2,3, Nobuaki Matsubara4
1Department of Breast and Medical Oncology National Cancer Center Hospital East Chiba Japan.
Introduction:
Urachal carcinoma is a rare cancer, manifesting predominantly as adenocarcinoma, and could be treated with chemotherapy in patients with advanced or recurrent disease. However, any standard chemotherapy regimens are yet to be determined.
Case Presentation:
We retrospectively reviewed five patients with urachal adenocarcinoma treated with a potent first-line chemotherapy, cisplatin and S-1, between 2011 and 2014. Among the five patients, three were males. The median age at diagnosis was 61 years, ranging from 47 to 67. The most common symptom at their first visit was macroscopic hematuria. The best response was stable disease in four patients, which persisted for 7 months. Three patients experienced only one episode of grade 3 toxicity. Cisplatin and S-1 was well tolerated and safe.
Conclusion:
The activity of cisplatin and S-1 is modest and more efficacious treatment is desired against urachal carcinoma.
More Related Videos
11:50Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
06:39Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Published on: November 22, 2019